Abstract:Background It is estimated that up to 5% of inflammatory bowel disease (IBD) patients have clinically significant liver disease due to multifactorial causes such as underlying Primary Sclerosing Cholangitis, pharmacotherapy, fatty liver disease or nodular regenerative hyperplasia. In recent years, transient elastography (TE), which uses the sonic detection of liver stiffness to predict hepatic fibrosis has increasingly replaced the need for a liver biopsy. It has been validated in patients with chronic hepatitis C as an accurate non-invasive predictor of advance fi brosis and cirrhosis. Aims Our aim was to evaluate the prevalence of clinically significant liver disease in IBD patients as defi ned by an increased liver stiffness measurement (LSM) using Transient Elastography (FibroScan®). Methods 110 random IBD patients and 55 non-IBD control patients (composed of patient relatives and hospital staff) had their LSM recorded. The median reading in kilopascals (kPa) of 10 successful acquisitions was recorded by a nurse trained in performing TE. Age, gender, body mass index (BMI), history of liver disease, presence of diabetes, number of cigarettes smoked and standard drinks of alcohol consumed per week, were recorded and entered as covariates in multivariate analysis. Results Of the 110 IBD patients, 71 (64.5%) had Crohn’s disease. There were no significant differences in mean age (43 ± 15 yrs vs. 41 ± 17 yrs), gender (males, 47% vs. 51%) and number of standard alcoholic drinks consumed per week (6 ± 9 vs. 4 ± 7) between IBD patients and non-IBD controls respectively (P > 0.05). IBD patients smoked significantly more cigarettes per week compared to non-IBD controls (15 ± 42 vs. 1 ± 6, P = 0.001). Four IBD patients had diabetes compared to none in the non-IBD group. Seven patients in the IBD group (6.4%) had an LSM reading of greater than 8 kPa compared to none in non-IBD control group. One patient, had an LSM of 14.9 kPa, normal liver function tests and evidence of portal hypertension on ultrasound. Although the overall LSM in the IBD group was higher, there was no statistical difference between the mean LSM reading of IBD patients (5.2 ± 2.5 kPa) and non-IBD controls (4.8 ± 1.2 kPa) on univariate (P = 0.22) and multivariate (P = 0.67) analysis. IBD patients had a significantly higher BMI compared to non-IBD controls (26 ± 4.6 vs. 24 ± 3.3, P = 0.04) and this was the only independent predictor of a high LSM reading on multivariate analysis (P < 0.0001). Conclusion IBD patients are more likely to have a higher BMI compared to non-IBD subjects and this is the main reason for their higher LSM reading. This implies that non-alcoholic fatty liver disease may be a significant cause of occult liver disease in IBD patients and attention should be paid to optimise metabolic risk factors such as minimising corticosteroid use.

Nonalcoholic Fatty Liver Disease Is Common in IBD Patients However Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare

P298 Risk factors for the progression of non-alcoholic fatty liver disease in people with inflammatory bowel disease

High Incidence of Non-Alcoholic Fatty Liver Disease in Patients with Crohn's Disease but Not Ulcerative Colitis

P172 Metabolic disorders with non-alcoholic fatty liver disease in people with inflammatory bowel disease

Fatty liver is associated with significant liver inflammation but does not increase fibrosis burden in Chronic Hepatitis B

Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study

Fatty liver is associated with significant liver inflammation but does not increase fibrosis burden in Chronic HBV infection

Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article

Fatty liver is associated with significant liver inflammation and increases the burden of advanced fibrosis in chronic HBV infection

Systematic Review With Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease

Non-alcoholic fatty liver degree and long-term risk of incident inflammatory bowel disease: A large-scale prospective cohort study

NAFLD, the changing face of IBD

Metabolic Dysfunction-Associated Fatty Liver Disease and Liver Function Markers Are Associated with Crohn's Disease but Not Ulcerative Colitis: a Prospective Cohort Study.

Non-alcoholic (metabolic associated) fatty liver disease in children with inflammatory bowel disease: current state of the problem

Complex dichotomous links of nonalcoholic fatty liver disease and inflammatory bowel disease: exploring risks, mechanisms, and management modalities

Nonalcoholic Fatty Liver Disease and the Intestinal Microbiome: An Inseparable Link

Multifaceted pathogenesis of liver steatosis in inflammatory bowel disease: a systematic review

Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future

Non-Invasive Serum Markers of Non-Alcoholic Fatty Liver Disease Fibrosis: Potential Tools for Detecting Patients with Cardiovascular Disease

Natural History of Nonalcoholic Fatty Liver Disease

Novel Serum Biomarkers for Noninvasive Diagnosis and Screening of Nonalcoholic Fatty Liver Disease-Related Hepatic Fibrosis.